라미부딘 내성 소아 청소년 만성 B형 간염에서 Entecavir 치료 경험
Experience with Entecavir Therapy for Lamivudine-Resistant Chronic Hepatitis B in Korean Children and Adolescents
조승만, 최병호, 김정미, 추미애,
소속 상세정보
조승만 ( Cho Seung-Man )
경북대학교 의학전문대학원 소아과학교실
최병호 ( Choe Byung-Ho )
경북대학교 의학전문대학원 소아과학교실
김정미 ( Kim Jung-mi )
경북대학교 의학전문대학원 소아과학교실
추미애 ( Chu Mi-Ae )
경북대학교 의학전문대학원 소아과학교실
KMID : 0816120100130010044
Abstract
Purpose: To estimate the viral suppressive effect of entecavir monotherapy in Korean children and adolescents with lamivudine-resistant chronic hepatitis B (CHB).
Methods: One milligram of entecavir was administered once daily to 6 patients (4 boys; mean age, 17.5 years; range, 15.10∼24.6 years) with lamivudine-resistant CHB for a mean duration of therapy of 13.4 months (range, 1∼21.1 months). The therapeutic results were compared with 11 patients who received adefovir (0.3 mg/kg/day [maximal dose 10 mg]) for at least 12 months (mean, 33.4 months; range, 12.4∼58.3 months). The serum HBV DNA level and serologic markers were measured every 2 months.
Results: The interval to a HBV DNA titer decrement (＞1 log10) was 1.2±0.2 and 4.4±5.2 months (p=0.185) for the entecavir and adefovir groups, respectively. The interval to a HBV DNA titer decrement (＞2 log10) was 2.4±2.3 and 9.2±7.3 months (p=0.025), for the entecavir and adefovir groups, respectively.
Conclusion: The therapeutic efficacy of entecavir was favorable in children and adolescents, especially in shortening the interval to a ＞2 log10 decrement in the HBV DNA titer. Long-term follow up is needed to determine the therapeutic efficacy of entecavir for lamivudine-resistant CHB in children and adolescents.
키워드
Entecavir; Adefovir; Lamivudine; Chronic hepatitis B; Resistance
원문 및 링크아웃 정보
등재저널 정보